Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2011

View Archived Issues

New tumor-homing peptide improves effects of IL-12 gene therapy in vivo

Long-term phase II data presented on eliglustat in type 1 Gaucher's disease

Final data disclosed from randomized menatetrenone trial in hepatocellular carcinoma

Appetite-regulating hormone gene mutation linked to panic disorder

Korean study identifies new risk factors for vascular dementia and Alzheimer's disease

AtheroNova and Maxwell Biotech sign deal for AHRO-001

Researchers at Incyte prepare new tyrosine-protein kinase JAK inhibitors

Novel IL-1 beta inhibitors presented by Ampla Pharmaceuticals

New PI3K-delta inhibitors disclosed by Roche

Genprex provides update on nanomolecular cancer therapy

BMS synthesizes novel inhibitors of DGL-alpha and DGL-beta

Dynavax Technologies receives NIAID grant

InterMune schedules Esbriet launch in Germany

Oncothyreon starts enrollment in phase II PX-866 trial

Novel IAP inhibitors patented by Aegera Therapeutics

Genentech submits NDA for vismodegib

New injectable sustained-release fluocinolone acetonide to enter clinic for posterior uveitis

ImmunoCellular Therapeutics reports updated data from phase I cancer vaccine trial

Moberg Derma completes recruitment in MOB-015 trial

BioSante Pharmaceuticals completes pharmacokinetic study of LibiGel

Abbott commences ABSORB BTK study

Inovio reports interim data from global HIV vaccine study

Studies evaluate GFT-505 in models of NAFLD/NASH

FDA lifts partial clinical hold on trial of NeuVax in breast cancer

Merck & Co. and BGI join to discover and develop biomarkers and genomic technologies

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...